The ability of CREBBP to modulate the TME through downregulation of MHC expression [57] combined with the potential for ARID1A to drive cell proliferation may be an important mechanism that drives high risk DLBCL. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.